Amikacin Infusion Rate
Administer intravenous amikacin over 30 to 60 minutes in adults, and over 30 to 60 minutes in pediatric patients (with infants receiving a 1 to 2 hour infusion). 1
Administration Details
The FDA-approved labeling provides explicit guidance on infusion timing that prioritizes safety by preventing excessive peak concentrations that could increase toxicity risk:
- Adults: Infuse over 30-60 minutes 1
- Pediatric patients: Infuse over 30-60 minutes 1
- Infants: Infuse over 1-2 hours 1
Preparation and Dosing Context
The solution is prepared by adding the contents of a 500 mg vial to 100 or 200 mL of sterile diluent (0.9% sodium chloride or 5% dextrose injection). The amount of fluid for pediatric patients should be sufficient to allow infusion over the recommended 30-60 minute period 1.
Standard dosing is 15 mg/kg/day (maximum 1.0 g/day) for adults, typically given as a single daily dose initially 2, 3, 2. For patients >59 years, reduce to 10 mg/kg/day (750 mg maximum) 2, 3, 2. The British Thoracic Society guidelines for NTM also describe alternative regimens including 7.5 mg/kg twice daily or 15-25 mg/kg three times per week 4.
Critical Safety Considerations
Why Infusion Rate Matters
The 30-60 minute infusion window is designed to:
- Prevent excessively high peak concentrations that increase ototoxicity and nephrotoxicity risk
- Allow adequate time for distribution while maintaining concentration-dependent bactericidal activity
- Enable appropriate therapeutic drug monitoring with predictable peak timing (90-120 minutes after infusion ends for accurate measurement) 4
Monitoring Requirements
Peak levels should be measured 90-120 minutes after infusion ends (or alternatively at 60 minutes, though this may underestimate true peak) 4. Target peaks are:
- 25-35 mg/L for daily dosing
- 65-80 mg/L for three times weekly dosing 4
Trough levels should be <5 mg/L to minimize nephrotoxicity and ototoxicity 4.
Common Pitfalls
- Do not administer as IV push or rapid bolus - this dramatically increases peak concentrations and toxicity risk
- Do not physically premix amikacin with other drugs - administer separately 1
- Adjust infusion time for infants - the longer 1-2 hour infusion in this population accounts for their different volume of distribution and clearance characteristics
- Monitor renal function closely - nephrotoxicity occurred in 8.7% of patients receiving amikacin, with higher rates in those with baseline renal impairment or receiving other nephrotoxic agents 2, 3, 2
The infusion rate is a critical parameter that directly impacts the safety profile of this aminoglycoside, particularly given that ototoxicity can be irreversible and nephrotoxicity risk increases with prolonged use 2, 4, 3, 2.